Vendor Intelligence Report: Shandong Nuoweiou Medical Technology Co

Published 14 Jun 2026. 15-page investigative report on who is behind Shandong Nuoweiou Medical Technology Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Shandong Nuoweiou is a narrow, recent dossier rather than a mature-vendor file. Across 5 Finnrick lab tests, the overall record is 4 pass / 1 fail, an 80% pass rate. All tested data is for tirzepatide; the samples show a strong chemical-identity and purity signal, but the buyer risk concentrates in fill accuracy and lot control rather than whether the molecule was present.

The tirzepatide trajectory is mixed in a buyer-relevant way. An August 2025 certificate documents a severe overfill on a 10 mg-labeled vial, followed by materially improved October results. That improvement is real, but four of five tested samples lacked batch identifiers, so the better certificates are hard to tie to a received vial or recallable lot. Nuoweiou also rates better under Finnrick’s public purity-weighted methodology than under stricter lenses focused on quantity and traceability.

The business record adds channel risk. Registry evidence shows a January 2025 Chinese entity capitalized at 30,000 RMB with a village-linked Jinan address; investigators found no verified manufacturing authority, no independent nuoweiou domain, and the known Alibaba storefront was offline with no Wayback capture. A 3-follower Facebook persona using a free 163.com email and a negative affiliate-code scan do not establish a reputation base; they mostly show a seller with little durable public infrastructure.

Inside the full report:

  • Finnrick tirzepatide certificates, including the August overfill event and later October certificates with improved quantity accuracy.
  • Per-product pass/fail rates and methodology-divergence charts for the single Finnrick-tested product.
  • Mingluji corporate-registry capture with formation date, capital, registered address, USCC, and legal-representative search views.
  • Infrastructure audit covering the offline Alibaba storefront, absent nuoweiou domains, zero Wayback captures, and the Facebook persona.
  • Regulatory/import checks across FDA DECRS, FDA device listing, Import Alert 66-80, and Chinese licensing evidence.
  • Community and promotion sweep covering X/web referral-code searches, PeptideAtlas and PeptideBenchmark captures, and Reddit coverage limits.

Risk assessment

  • Tirzepatide dosing-accuracy risk — high: One 10 mg Tirzepatide sample tested at 18.81 mg (+88.1% overfill); later Tirzepatide samples improved but included +14.0% and +16.7% overfills before October.
  • Tirzepatide traceability / recall risk — high: Four of five Tirzepatide samples carried no batch identifier, including the improved October tests, leaving no practical batch-level recall path.
  • Corporate and channel-continuity risk — high: Jan. 2025 entity with 30,000 RMB capital, village-linked address, no independent domain, and its only known Alibaba storefront offline/404.
  • Regulatory/import-compliance risk — high: No FDA drug/device establishment registration found, not identified on FDA Import Alert 66-80 Green List, and no verifiable Chinese drug-manufacturing/wholesale permits in the supplied record.